ライフサイエンスコーパス: fasting blood glucose

1 cardiovascular risk factors (cholesterol and fasting blood glucose).

2 t being associated with liver enzymes or non-fasting blood glucose.

3 such as triglycerides, HDL cholesterol, and fasting blood glucose.

4 ecreased pancreatic beta cell mass, and high fasting blood glucose.

5 t diabetes of >/=2 wk duration that measured fasting blood glucose.

6 inal 3 weeks of the diet exhibited decreased fasting blood glucose.

7 d in significantly but only slightly lowered fasting blood glucose (-0.14 mmol/L; 95% CI: -0.24, -0.0

8 ood pressure (-1.11 mm Hg [-1.78 to -0.44]), fasting blood glucose (-1.81 mg/dL [-3.33 to -0.28]), HD

9 CI: -3.72, -0.83, p = 0.002), and increased fasting blood glucose (16.14 mg/dL 95% CI: 6.25, 26.04,

10 emoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), fasting blood glucose (-37.8 +/- 70.4 mg/dL, P < 0.001)

11 = 55 (2.9%)), and impaired fasting glucose (fasting blood glucose 5.6-6.9 mmol/L; n = 744 (38.8%)).

12 rediabetes was a 0.2 mmol l(-1) reduction in fasting blood glucose (95% confidence interval -0.44 to

13 Apo AII, Apo B, CRP, TNF-alpha, glucose, and fasting blood glucose among diabetic and cardiovascular

14 e had poor metabolic control, with 497 mg/dl fasting blood glucose and 15.6% HbA1c.

15 cal health measurements for body mass index, fasting blood glucose and blood pressure were obtained.

16 Lower glycemic index (GI) diets reduced both fasting blood glucose and glycated proteins independentl

17 MTZ reduced fasting blood glucose and HbA(1c) levels in db/db mice,

18 d pressure among hypertensive patients, mean fasting blood glucose and HbA1c among type II diabetic p

19 Fasting blood glucose and HbA1c levels, retinopathy, lip

20 elafin levels are inversely correlated with fasting blood glucose and hemoglobin A1c levels in men w

21 s GCK, has been reproducibly associated with fasting blood glucose and hemoglobin A1c.

22 Rb1 also significantly decreased fasting blood glucose and improved glucose tolerance, an

23 Gcgr(Hep)(-/-) mice exhibited reductions in fasting blood glucose and improvements in insulin sensit

24 The main outcomes analyzed were fasting blood glucose and insulin as well as fasting tri

25 ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved gl

26 ount of total visceral adipose tissue (VAT), fasting blood glucose and insulin levels, homeostasis mo

27 nificantly associated with liability to T2D, fasting blood glucose and insulin resistance; (v) DNA me

28 bolism markers [glycated hemoglobin (HbA1c), fasting blood glucose and insulin, HOMA-IR)].

29 Fasting blood glucose and lipid levels, the results of a

30 Fasting blood glucose and lipids did not differ, yet SM2

31 econdary outcomes (including blood pressure, fasting blood glucose and lipids) were assessed in a sur

32 of diabetes, XMetA markedly reduced elevated fasting blood glucose and normalized glucose tolerance.

33 PDX-1(+/-) mice had a normal fasting blood glucose and pancreatic insulin content but

34 The mice maintained a normal level of fasting blood glucose and responded to the diabetogenic

35 atonin (MTNR1B) is associated with increased fasting blood glucose and risk of T2D, but whether sleep

36 N-ethylcarboxamidoadensoine (NECA) increased fasting blood glucose and slowed glucose disposal during

37 sured blood pressure, body mass index (BMI), fasting blood glucose and total cholesterol, and self-re

38 ncluding blood pressure, waist to hip ratio, fasting blood glucose and triglyceride levels.

39 valuated for impaired glucose homeostasis by fasting blood glucose and/or oral glucose tolerance test

40 terol, total cholesterol, triglycerides, and fasting blood glucose) and identified several cis-eGenes

41 th CVD risk factors (lipids, blood pressure, fasting blood glucose, and body mass index) in the same

42 mference, triglycerides, blood pressure, and fasting blood glucose, and decreased high-density lipopr

43 eta-cell display improved glucose tolerance, fasting blood glucose, and GSIS, whereas G6PC2 levels ar

44 n hypothalamus by ASO increased food intake, fasting blood glucose, and hepatic glucose output, decre

45 ug/kg) improved glucose tolerance, decreased fasting blood glucose, and increased insulin-stimulated

46 ce test (GTT), insulin tolerance test (ITT), fasting blood glucose, and insulin levels were used to a

47 o be significant (P <0.05), for BW, WC, BMI, fasting blood glucose, and IPGTT-AUC.

48 ffects on [(18)F]FDG-PET, fasting C-peptide, fasting blood glucose, and pS6.

49 s between body mass index, percent body fat, fasting blood glucose, and serum alanine transaminase le

50 od samples were assessed for hemoglobin A1c, fasting blood glucose, and serum lipids.

51 or P25-complex tocotrienol) on blood lipids, fasting blood glucose, and the excretion of 8-iso-prosta

52 sity lipoprotein cholesterol, triglycerides, fasting blood glucose, and the Framingham Cardiovascular

53 ting systolic and diastolic blood pressures, fasting blood glucose, and total cholesterol.

54 1, when dosed orally, was found to decrease fasting blood glucose at 30 mg/kg in a streptozotocin-tr

55 All remaining recipients with two fasting blood glucoses between 5.6 and 6.9 mmol/L were i

56 ificant improvements were observed in HbA1c, fasting blood glucose, blood pressure, blood lipid profi

57 omes were changes in hemoglobin A1c (HbA1c), fasting blood glucose, blood pressure, lipids, and diet.

58 diation by mid-life systolic blood pressure, fasting blood glucose, body mass index, and smoking.

59 In each of the 3 trials, baseline fasting blood glucose, body mass index, hypertension, an

60 erol; apolipoprotein A1 or B; triglycerides; fasting blood glucose; body mass index; body weight; wai

61 betic mice, Ad-hACE2-eGFP treatment improved fasting blood glucose but had no effect on any of the ot

62 mg/kg/day for 2 weeks significantly reduced fasting blood glucose by 18%, with significant increase

63 receptor modulator, to db/db mice normalizes fasting blood glucose by increasing beta-cell mass and b

64 esults of biochemical parameters showed that fasting blood glucose, C-peptide, fructosamine, triglyce

65 Medical history, a fasting blood glucose, calcineurin inhibitor blood level

66 ciency is associated with elevated levels of fasting blood glucose, circulating insulin, cholesterol

67 G4KO mice exhibited elevated fasting blood glucose compared with C57BL/6J mice.

68 nts exhibited significantly lower random and fasting blood glucose compared with mice transplanted wi

69 ry outcome was a 0.3 mmol l(-1) reduction in fasting blood glucose compared with placebo from baselin

70 (-1.87 cm (95% CI: -3.32, -0.44) P = 0.011), fasting blood glucose concentration (-6.48 mg/dL (95% CI

71 In people without diabetes, fasting blood glucose concentration is modestly and non-

72 out a history of diabetes, information about fasting blood glucose concentration or impaired fasting

73 Fasting blood glucose concentration was non-linearly rel

74 -analysis of individual records of diabetes, fasting blood glucose concentration, and other risk fact

75 d its components-abdominal obesity, elevated fasting blood glucose concentration, low high-density li

76 The intervention showed an effect on fasting blood glucose concentrations (-6.95 mg/dL (95% C

77 Primary outcomes were assessed through fasting blood glucose concentrations and 2-h oral glucos

78 educed offspring weight post-weaning, higher fasting blood glucose concentrations and greater gonadal

79 iagnosis of diabetes mellitus rely mainly on fasting blood glucose concentrations and use a lower cut

80 show that acute ethanol exposure also lowers fasting blood glucose concentrations by inhibiting the C

81 Compared with fasting blood glucose concentrations of 3.90-5.59 mmol/L

82 se effects were greater in persons with poor fasting blood glucose control.

83 At 12-month follow-up, the mean fasting blood glucose decreased by 22.86 mg/dL in the in

84 avoring the intervention were also noted for fasting blood glucose, diastolic blood pressure, and die

85 Body weight and fasting blood glucose did not differ between wild-type a

86 Age, family history, Fasting Blood Glucose, dyslipidaemia, lipid profile, par

87 Body weight, organ mass, fasting blood glucose, energy expenditure, cardiac geome

88 Posttransplant DM was screened for by fasting blood glucoses every 1-3 months.

89 for complex survey design were used in which fasting blood glucose, fasting insulin, and HbA1c were o

90 Fasting blood glucose, fasting insulin, and insulin tole

91 The mice also had elevated fasting blood glucose, fatty liver, and insulin resistan

92 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) l

93 Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) l

94 tween participants with high vs. low average fasting blood glucose (FBG) and homeostasis model assess

95 all three genes were associated with either fasting blood glucose (FBG) and/or 2-h blood glucose (BG

96 ) showed significant improvement in both the fasting blood glucose (FBG) concentration (-37.0 mg/dL;

97 Among nondiabetic individuals, higher fasting blood glucose (FBG) independently predicts diabe

98 Elevated fasting blood glucose (FBG) is associated with increased

99 Elevated fasting blood glucose (FBG) is associated with increased

100 s glycated hemoglobin (A1C) less than 6% and fasting blood glucose (FBG) less than 100 mg/dL off diab

101 Fasting blood glucose (FBG) levels fell from 11.9 +/- 1.

102 We abstracted all outpatient fasting blood glucose (FBG) levels for up to 60 months b

103 mportant common determinant of variations in fasting blood glucose (FBG) levels in humans.

104 na and stroke, while diabetes was defined by fasting blood glucose (FBG) of > 100 mg/dL and HbA1c of

105 Glycosylated hemoglobin (HbA1c) and fasting blood glucose (FBG) sensitivity in defining dysg

106 The fasting blood glucose (FBG) values extracted from electr

107 iated negatively with Waist hip ratio (WHR), fasting blood glucose (FBG), 2-hour blood glucose after

108 f glucomannan on plasma lipids, body weight, fasting blood glucose (FBG), and blood pressure (BP), bu

109 or body fat mass (BFM) with blood pressure, fasting blood glucose (FBG), and urinary kidney injury m

110 ween phthalate metabolite concentrations and fasting blood glucose (FBG), homeostasis model assessmen

111 igh-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), hsCRP, TNF-alpha, PAI-1, an

112 Except for fasting blood glucose (FBG), hypertension (HTN), and Typ

113 ugh this was not associated with a change in fasting blood glucose (FBG), or GSIS from isolated islet

114 a period of 8 weeks posttransplant to assess fasting blood glucose (FBG), serum insulin (SI) levels,

115 od samples for biomarker analysis, including fasting blood glucose (FBG), total cholesterol (TC), tri

116 response (AIR), disposition index (DI), and fasting blood glucose (FBG)--using generalized estimatin

117 n secretion to glucose and thereby regulates fasting blood glucose (FBG).

118 he action of glucokinase, thereby regulating fasting blood glucose (FBG).

119 etS are described by WC, followed by TG then fasting blood glucose (FBG).

120 /- SD: GDR 15.8 +/- 2.0 mg. kg(-1). min(-1), fasting blood glucose [FBG] 4.7 +/- 0.3 mmol/l, BMI 26 +

121 lycemic control (random blood glucose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [Hb

122 ght and cardiometabolic risk factor changes (fasting blood glucose [FBG], glycosylated hemoglobin [Hb

123 No differences in fasting blood glucose (FBS), random blood glucose (RBS),

124 Associations with fasting blood glucose (FG) and fasting insulin, 2-h post

125 The primary outcome was the change in mean fasting blood glucose from baseline to 12-month follow-u

126 BDNF treatment normalized fasting blood glucose from initially hyperglycemic level

127 systolic and diastolic blood pressure (BP), fasting blood glucose, glycated hemoglobin (HbA1c), trig

128 assessed with use of measurements of HbA1c, fasting blood glucose, glycemic variability assessed wit

129 35 inches (women) or > or = 40 inches (men); fasting blood glucose > or = 100 mg/dL; serum triglyceri

130 that 4 factors independently predicted NOD: fasting blood glucose >100 mg/dl, fasting triglycerides

131 s were markedly hyperglycemic pretransplant (fasting blood glucose >300 mg/dl).

132 Of the NOD mice, 11 and 70% had diabetes (fasting blood glucose >8.3 mmol/l) at 13 and 18 weeks of

133 use; n = 163 (8.5%)), undiagnosed diabetes (fasting blood glucose >or=7.0 mmol/L without diagnosed d

134 In T2D, FKBPL was negatively correlated with fasting blood glucose, HbA1c and diastolic blood pressur

135 PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweigh

136 acists' interventions significantly improved fasting blood glucose, HbA1c, lipid parameters, blood pr

137 arkers: waist circumference, blood pressure, fasting blood glucose, HDL-cholesterol, triglycerides.

138 DL-cholesterol, triglycerides and potassium, fasting blood glucose, heart rate, and bodyweight on dif

139 gion, socioeconomic status, body mass index, fasting blood glucose, hemoglobin A1c, and lipid profile

140 isk factors, such that adolescents with high fasting blood glucose, high hemoglobin A1c, high triglyc

141 ed with a higher risk of developing elevated fasting blood glucose (HR = 1.33, 95% CI: 1.14, 1.56).

142 c activator, CDN1163, which markedly lowered fasting blood glucose, improved glucose tolerance, and a

143 f E6 significantly decreased body weight and fasting blood glucose, improved lipid metabolism, and al

144 We found that treatment with ApoA-IV lowered fasting blood glucose in both WT and diabetic KKAy mice

145 s glucose tolerance, insulin sensitivity and fasting blood glucose in diet-induced obesity (DIO) and

146 Particulate air pollution and fasting blood glucose in nondiabetic individuals: associ

147 -1 receptor antagonist exendin-(9-39) raises fasting blood glucose in normal mice.

148 il, and 20.4% protein, significantly lowered fasting blood glucose in obese, hyperglycemic mice.

149 to examine the effects of exendin-(9-39) on fasting blood glucose in subjects with K(ATP)HI.

150 e we examine the effect of exendin-(9-39) on fasting blood glucose in SUR-1(-/-) mice.

151 mol/l) resulted in a concentration-dependent fasting blood glucose-independent induction of both endo

152 4-76) (the putative secreted domain) reduces fasting blood glucose independently of body weight chang

153 In both lines, fasting blood glucose initially declined equally.

154 Fasting blood glucose, insulin sensitivity, and beta-cel

155 Nat1-deficient mice had elevations in fasting blood glucose, insulin, and triglycerides and de

156 d its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insulin, and triglycerides.The ob

157 dy composition (by DXA), blood pressure, and fasting blood glucose, insulin, C-peptide, and lipids.

158 IRKO mice had fasting blood glucose, insulin, free fatty acid, and tri

159 rotein-a, high-sensitive C-reactive protein, fasting blood glucose, insulin, interleukin-6 (IL-6), tu

160 All recipients had normal levels of fasting blood glucose, intravenous glucose tolerance, an

161 Fasting blood glucose is also reduced.

162 One means to lower fasting blood glucose is to reduce the glucose output of

163 -wide association study gene associated with fasting blood glucose, is a negative regulator of glucos

164 ulin glargine) with dose titration targeting fasting blood glucose less than 110 mg/dL.

165 rovement, as measured by change in mean (SD) fasting blood glucose level (-45.9 [45.9] mg/dL [95% CI,

166 ence interval (CI): 1.06, 1.52), an elevated fasting blood glucose level (HR = 1.20, 95% CI: 1.03, 1.

167 -2.2% [CI, -2.9% to -1.4%]) (24 studies) and fasting blood glucose level (net change, -0.12 mmol/L [-

168 Pigs receiving IDN6556 had lower fasting blood glucose level after transplantation and a

169 Type 2 diabetes, defined as a fasting blood glucose level greater than or equal to 126

170 Fasting blood glucose level increased an average of 0.3

171 s to receive insulin glargine (with a target fasting blood glucose level of </=95 mg per deciliter [5

172 poorly controlled diabetes mellitus, with a fasting blood glucose level of 410 mg/dL (22.8 mmol/L) a

173 At baseline, the mean (SD) fasting blood glucose level was 156.06 (44.48) mg/dL (15

174 once daily for 5 weeks, maintained a steady fasting blood glucose level with a significant increase

175 ipocyte proliferation, hepatic inflammation, fasting blood glucose level, and glucose intolerance, co

176 d include demographic data, blood pressures, fasting blood glucose level, and lipid profile.

177 ing primary end points included weight loss, fasting blood glucose level, headache, urinary tract inf

178 The outcome variables include fasting blood glucose level, high blood glucose, and sel

179 rotein), glycated hemoglobin level, and mean fasting blood glucose level.

180 poprotein cholesterol (LDL-cholesterol), and fasting blood glucose level.

181 K-treated diabetic mice displayed normalized fasting blood glucose levels (95 +/- 4.8 mg/dl; P < 0.00

182 Hemoglobin A1c (HbA1c) and fasting blood glucose levels (FBGLs) were recorded.

183 ng depth [PD], marginal bone loss [MBL]) and fasting blood glucose levels (FBGLs) were recorded.

184 days (short term) resulted in a decrease in fasting blood glucose levels (from 173 +/- 11 mg dl-1 on

185 nitored for dietary intake, body weight, and fasting blood glucose levels after islet transplantation

186 Allograft survival was determined by fasting blood glucose levels and flow cytometric techniq

187 ed with 5-thio-glucose was impaired, whereas fasting blood glucose levels and food intake after an ov

188 with XBP1 depletion significantly increases fasting blood glucose levels and gluconeogenic gene expr

189 ved that oral administration of ANC improved fasting blood glucose levels and glucose tolerance in hy

190 pha2 subunits exhibited significantly higher fasting blood glucose levels and produced more glucose t

191 The effect of HNP-1 on fasting blood glucose levels and the expression of hepat

192 Fasting blood glucose levels and those after a glucose t

193 Fasting blood glucose levels averaged 12.1 +/- 1.1 (mean

194 Aqp7-/- mice exhibited normal fasting blood glucose levels but elevated blood insulin

195 zations of Cyp46a1(-/-) mice that had normal fasting blood glucose levels but up to a 1.8-fold increa

196 After 12 weeks, mean (+/-SE) HbA1c and fasting blood glucose levels decreased with active thera

197 In addition, fasting blood glucose levels for DKO mice were significa

198 ur (CDSF) were effective in acutely lowering fasting blood glucose levels in diet induced obese hyper

199 Transplantation normalized fasting blood glucose levels in nine out of nine dogs fo

200 liver was also evident from markedly reduced fasting blood glucose levels in ob/ob-klotho DKO mice, c

201 ion of pure D3S5G dose-dependently decreased fasting blood glucose levels in obese C57BL/6J mice, and

202 found to be more a more sensitive test than fasting blood glucose levels in PTDM, with 10.1% of all

203 Fasting blood glucose levels in SUR-1(-/-) mice treated

204 injection directly into the VMN also lowered fasting blood glucose levels in uncontrolled insulin-def

205 a higher percentage (100% vs. 33.3%) showed fasting blood glucose levels less than 11 mM.

206 In contrast, the lowered fasting blood glucose levels observed in ghrelin recepto

207 ixed doses of 150, 250, and 400 U to achieve fasting blood glucose levels of 80 to 130 mg per decilit

208 provement in glucose tolerance and had lower fasting blood glucose levels than Av3Null-treated mice.

209 Mean fasting blood glucose levels were equivalent between gro

210 Fasting blood glucose levels were measured using a gluco

211 Fasting blood glucose levels were monitored for 14 days.

212 ed diabetic rats revealed the following: (1) fasting blood glucose levels were reduced to normal; (2)

213 Mean fasting blood glucose levels were significantly higher i

214 After cessation of sub-acute dosing, fasting blood glucose levels were significantly lower in

215 Fasting blood glucose levels were similar among age-matc

216 othelium resulted in significantly increased fasting blood glucose levels, a blunted insulin response

217 tudy, treatment with Rhodiola rosea improved fasting blood glucose levels, altered the response to ex

218 Cardiovascular disease risk factors, fasting blood glucose levels, and diabetes medication hi

219 the liver augments gluconeogenesis, raising fasting blood glucose levels, and hepatic FoxO6 depletio

220 (NAG-1 Tg) mice exhibited lower body weight, fasting blood glucose levels, and serum insulin levels t

221 n receptor null mice and also helps maintain fasting blood glucose levels, ensuring an adequate suppl

222 ignificantly (p < 0.01) decreased random non-fasting blood glucose levels, from 351 +/- 20 mg/dl to a

223 Lower fasting blood glucose levels, higher insulin, and lower

224 Fasting blood glucose levels, medication type and dose,

225 of 1-10), consisting of duration of obesity, fasting blood glucose levels, the presence of high blood

226 mice promoted gluconeogenesis and increased fasting blood glucose levels.

227 th lean and obese mice resulted in decreased fasting blood glucose levels.

228 have been made at least weekly, according to fasting blood glucose levels.

229 f ABA extract in the DIO model and increased fasting blood glucose levels.

230 O1 protein levels in fasted mice, as well as fasting blood glucose levels.

231 ed gluconeogenesis, glucose intolerance, and fasting blood glucose levels.

232 econdary outcomes (including blood pressure, fasting blood glucose, lipids) were assessed after 4 yea

233 dults (n = 31, 65 +/- 8 years) with baseline fasting blood glucose < 100 mg/dL.

234 dL, untreated blood pressure <120/<80 mm Hg, fasting blood glucose <100 mg/dL, and ideal physical act

235 edication use and the proportion controlled (fasting: blood glucose <126 mg/dL; nonfasting: <=180 mg/

236 by using self-administered questionnaires, a fasting blood glucose measurement, a 2-h oral-glucose-to

237 lated as Ln [fasting triglycerides (mg/dL) x fasting blood glucose (mg/dL)/2], and a group-based traj

238 In vivo, transgene induction lowered fasting blood glucose, mimicking EIHI.

239 Conversely, the immediate reductions in fasting blood glucose observed with acute amlexanox trea

240 Diabetes was defined as a fasting blood glucose of 126 mg/dl or more or pharmacolo

241 g) or glargine (100 U/mL), titrated to reach fasting blood glucose of less than 100 mg/dL.

242 smetabolism in these patients than levels of fasting blood glucose or glycated hemoglobin.

243 nificant correlation between body weight and fasting blood glucose ( P < 0.001) over time.

244 score was associated with 0.46 mg/dL higher fasting blood glucose (p = .0038), and a 1-unit-higher o

245 egative correlation between islet number and fasting blood glucose (P = 0.02).

246 Serum fasting blood glucose, peak amylase, and serial amylase

247 level, homocysteine level, leukocyte count, fasting blood glucose, periodontal disease, ankle-brachi

248 tein, ankle-brachial index, leukocyte count, fasting blood glucose, periodontal disease, carotid inti

249 x, and PISA) and systemic parameters (HbA1c, fasting blood glucose, post prandial blood glucose, urin

250 s on glycemic regulation, including reducing fasting blood glucose, postprandial glucose and insulin

251 Diastolic dysfunction was correlated with fasting blood glucose (r = .69, P < .006) but not with p

252 %), blood pressure (range, 11.9%-16.3%), and fasting blood glucose (range, 31.2%-42.9%) were lower in

253 Fasting blood glucose remained normal in the mice even a

254 Our findings for metabolic syndrome and high fasting blood glucose remained significant for PM2.5 lev

255 controls, constructing temporal profiles of fasting blood glucose, serum lipids including triglyceri

256 tion with AAA mortality (P</=0.007), whereas fasting blood glucose showed no association.

257 factors (blood pressure, total cholesterol, fasting blood glucose, smoking) were defined as poor, in

258 Liver weight, fasting blood glucose, steatosis, lobular inflammation a

259 cing the levels of HbA1c (SUCRA: 92.33%) and fasting blood glucose (SUCRA: 85.92%).

260 -density lipoprotein, and total cholesterol, fasting blood glucose, systolic and diastolic blood pres

261 s based on anxiety score, depression scores, fasting blood glucose, systolic blood pressure, and hist

262 f white adipose tissue, and a slightly lower fasting blood glucose than controls.

263 analyzed the relationship of diabetes and of fasting blood glucose to the level of pulmonary function

264 Weight loss significantly reduced fasting blood glucose, total cholesterol, triglycerides,

265 collected blood samples from subjects whose fasting blood glucose transitioned to a level consistent

266 tary fiber for reducing the levels of HbA1c, fasting blood glucose, triglycerides, and LDL cholestero

267 apoptosis (r = 0.10, P = 0.65), whereas the fasting blood glucose was (r = 0.77, P < 0.001).

268 Fasting blood glucose was 91 +/- 10 mg/dL at baseline fo

269 Fasting blood glucose was increased in high-fat compared

270 Because EGP is a primary determinant of fasting blood glucose, we hypothesize that a protective

271 T2D mice, NR greatly reduced non-fasting and fasting blood glucose, weight gain and hepatic steatosis

272 ticipants, systolic blood pressure (SBP) and fasting blood glucose were also contributors, and WMH vo

273 diagnosis of diabetes and a higher level of fasting blood glucose were associated with lower than pr

274 e systolic and diastolic blood pressures and fasting blood glucose were consistently associated with

275 Blood pressure and fasting blood glucose were not significantly associated

276 hibited enhanced insulin secretion and lower fasting blood glucose within 8 weeks of birth, but reduc

277 fied a quantitative trait locus that affects fasting blood glucose within the Framingham Heart Study

278 no significant effect of nut consumption on fasting blood glucose (WMD: -0.52 mg/dL; 95% CI: -1.43,